Article: Hong Kong scientist behind artificial ‘mini-hearts’ takes Novoheart closer to China with facilities to quicken drug discovery process

Image for Article: Hong Kong scientist behind artificial ‘mini-hearts’ takes Novoheart closer to China with facilities to quicken drug discovery process

Article Details

Impact Score

5 / 10

AI Summary (Processed Content)

Novoheart, a biotech firm known for creating artificial 'mini-hearts,' is expanding its presence in Hong Kong and mainland China with new facilities. The company's CEO cites access to talent and the large Chinese pharmaceutical market as key reasons for the move, with total spending exceeding HK$200 million.

The new Hong Kong laboratory will focus on heart tissue engineering and aims to produce clinical-grade materials. The location also provides easier access to biological materials from Chinese patients, which is advantageous for researching diseases prevalent in Asian populations.

The main topics covered are Novoheart's strategic expansion into Hong Kong and China, the commercialization of its heart technology, and the advantages of accessing the regional talent pool and pharmaceutical market.

Original URL

https://www.scmp.com/business/china-business/article/3103995/hong-kong-scientist-behind-artificial-mini-hearts-takes?utm_source=rss_feed

Source Feed

Science & Research - South China Morning Post

Published Date

2020-10-02 12:03

Fetched Date

2026-03-04 14:32

Processed Date

2026-03-04 15:13

Embedding Status

Present

Cluster ID

Not Clustered

Raw Extracted Content

Hong Kong scientist behind artificial ‘mini-hearts’ takes Novoheart closer to China with facilities to quicken drug discovery process
- Company behind ‘mini-hearts’ innovation sets up laboratory in Hong Kong to get closer to talents and access to markets
- Hong Kong scientist is taking Canada-listed Novoheart private, does not rule out tapping local capital market for funds
The Canada-listed firm sees Hong Kong as part of its global efforts to access a deep pool of talents and markets, co-founder and chief executive officer Ronald Li said. Including new facilities in Wuxi in mainland China’s southern Jiangsu province, and in eastern US, its spending will exceed HK$200 million (US$25.8 million), he added.
“It is not uncommon for early- to mid-stage biotechnology firms to have multiple sites, to recruit the right people,” Li said in an interview. “We are expanding despite the global economic uncertainties, because our technology is ready for commercialisation.”
A presence in Hong Kong could be a springboard for the firm to get nearer to the world’s largest market. China’s pharmaceutical market increased from US$194.3 billion in 2015 to US$236.3 billion in 2019, according to Frost & Sullivan. The size is forecast to reach US$322.6 billion in 2024, it said.
Novoheart opened a 16,000-sq ft laboratory and office in Kwun Tong last week, which will focus on heart tissues engineering. It plans to expand its facilities at the Hong Kong Science and Technology Park in Pak Shek Kok to be able to produce “clinical-grade” materials that can be used on patients.
“A major advantage of Hong Kong is that if we want to focus on certain diseases prevalent among Asians, we can access Chinese patient materials easily here,” said Li, who co-founded the venture in 2015.